The UK and US have established a significant bilateral deal that will guarantee no tariffs on British drug shipments entering the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to boost spending on drugs through the National Health Service (NHS). This pledge guarantees that duties on these vital exports will remain at zero for a duration of the next three years.
This development follows earlier threats to dramatically increase import taxes on branded pharmaceutical imports, with potential rates discussed up to double the cost.
"This deal between the United Kingdom reinforces the global environment for new treatments and establishes much-needed equity to transatlantic pharmaceutical trade," a statement said.
Economic Impact
Medicines are one of the UK's most significant goods shipped to the United States, which is easily the primary market for leading companies like GSK and AstraZeneca.
Export figures show that in the 12 months to the end of September, the UK sold medicines totaling over eleven billion pounds to the US. This value made up nearly one-fifth of all goods exports in that span.
"This agreement protects jobs, increases funding and paves the way for the UK to become a global hub for biotech and pharma," the Business and Trade Secretary commented.
Key NHS Changes
The agreement includes several notable changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise overall NHS spending on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum pharmaceutical firms must refund to the NHS to prevent overspending will be restricted at fifteen percent. Last year, repayments were more than twenty percent.
Industry Background
The pact comes amid a ongoing dispute between the sector and the UK government over drug pricing and approval rates.
These tensions were intensified by claims that US patients were charged several times more for the same drugs than patients in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been delayed or abandoned, while major expansions have been announced toward American operations.
One official acknowledged that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the previous ten-year period.
